¿¬¼ö°­ÁÂ
´ëÇÑÀü¸³¼±ÇÐȸ 2024 KPS Annual Prostate International Meeting : 2024-03-09

´ëÇÑÀü¸³¼±ÇÐȸ 2024 KPS Annual Prostate International Meeting : 2024-03-09
±³À°ÀÏÀÚ : 2024-03-09
±³À°Àå¼Ò : ¼­¿ï SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀǽÇ

±³À°ÁÖÁ¦ : 2024 KPS Annual Prostate International Meeting

ÁÖÃÖ±â°ü : ´ëÇÑÀü¸³¼±ÇÐȸ
´ã´çÀÚ : ÇãÀçÀº
¿¬¶ôó : 02-6956-7967  

À̸ÞÀÏ : gaonpco@gaonpco.com

±³À°Á¾·ù : ºñ´¢ÀÇÇаú, ÀÇ»çÇÐ, ÀÇÇб³À°

Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 40,000¿ø  

ºñ°í - »çÀüµî·Ï: 3¸¸¿ø(Àü¹®ÀÇ, ¿¬±¸¿ø, °£È£»ç) / ¹«·á(Àü°øÀÇ, Çлý) - ÇöÀåµî·Ï: 4¸¸¿ø(Àü¹®ÀÇ, ¿¬±¸¿ø, °£È£»ç) / ¹«·á(Àü°øÀÇ,Çлý) - ¿Ü±¹ÀÎ Âü¿©ÀÚ: ¹«·á


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 09:00~10:00 Prostate cancer, etc Á¶¹®±â(¿øÀڷº´¿ø)

±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 10:00~10:20 Surgery as radical local treatment (as part of a multimodality approach) Á¶Á¤±â(ÇѾçÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 10:20~10:40 Radiation therapy as radical local treatment (as part of a multimodality approach) ±¸±³Ã¶(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 10:40~11:00 Neoadjuvant Lutetium therapy before RP in high risk PCa patients Nathan LAWRENTSCHUK(University of Melbourne)

Åä·Ð 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 11:00~11:10 Case-Based Panel Discussion : Presentation Case 1, 2 °­µ¿Çõ, ÀÌÁ¾¼ö, ¼­¿øÀÍ, ÃÖ¼¼¿µ(ÀÎÇÏÀÇ´ë, ¿¬¼¼ÀÇ´ë, ÀÎÁ¦ÀÇ´ë, Áß¾ÓÀÇ´ë)

ÈÞ½Ä 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 11:10~11:25 Coffee Break ()

±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 11:25~11:45 A quest for consensus on focal therapy for prostate cancer Rafael SANCHEZ-SALAS(McGill University in Montreal, Quebec)

±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 11:45~12:05 Focal therapy in prostate cancer: Friend or Foe Behfar EHDAIE(Memorial Sloan-Kettering Cancer Center)

±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 12:05~12:25 How should clinicians confirm if a patient is a candidate for focal therapy and define successful treatment? ÀÌÇйÎ(¼­¿ïÀÇ´ë)

Åä·Ð 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 12:25~12:45 Case-Based Panel Discussion : Presentation Case 1, 2 ÀÌÁ¤¿ì, ½Åµ¿È£, ±èÅÂÈ¿, ¼ÛÇÊÇö(°æÈñÀÇ´ë, °¡Å縯°üµ¿ÀÇ´ë, µ¿¾ÆÀÇ´ë, ¿µ³²ÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 12:45~13:00 Optimal choice in the 1st line mHSPC treatment with apalutamide Á¤°æÁø(°¡ÃµÀÇ´ë)

½Ä»ç 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 13:00~13:45 lunch ()

±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 13:45~14:00 Prostate International: past, present, and future Á¤Àç½Â(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 14:00~14:20 CRPC: How to best sequence therapies in real life Daniel DANILA(Memorial Sloan-Kettering Cancer Center)

±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 14:20~14:40 Current role of PSMA-based radioligand therapy for mCRPC ¹ÚÀ翵(°í·ÁÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 14:40~15:00 The advent of PARP inhibitors for specific to all-comer application- 1) only for specific patients ¼Û¿Ï(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 15:00~15:20 The advent of PARP inhibitors for specific to all-comer application- 2) for all-comer patients Á¤À翵(±¹¸³¾Ï¼¾ÅÍ)

ÈÞ½Ä 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 15:20~15:35 Coffee Break ()

±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 15:35~15:55 Laser and robotics enucleastion ¼Û»óÈÆ(¿ï»êÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 15:55~16:15 Vaporization and aqua-ablation ±è¸í(ÀÌÈ­ÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ ÁöÇÏ1Ãþ ±¹Á¦È¸ÀÇ½Ç 16:15~16:35 Should we abandon TURP? Stavros GRAVAS(University of Cyprus )

 

  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] ´ëÇÑÇǺΰúÀÇ»çȸ ⸳ 20Áֳ⠱â³äÇà»ç ¹× Á¦21ȸ Ãß°èÇмú´ëȸ : 2018-11-04

±³À°ÀÏÀÚ : 2018-11-04 ±³À°Àå¼Ò : ±×·£µåÈúÆ°È£ÅÚ(È«Àºµ¿) ÄÁº¥¼Ç¼¾ÅÍ ¿Ü ±³À°ÁÖÁ¦ : ´ëÇÑÇǺΰúÀÇ»çȸ ⸳ 20Áֳ⠱â³äÇà»ç ¹× Á¦21ȸ Ãß°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇÑ

Ãßõ¼ö : 0 , Á¶È¸¼ö : 11,028 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­Á : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : ¿Â¶óÀÎ »ýÁß°è ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ ´ã´çÀÚ : °û¼ÖÀÌ ¿¬¶ôó : 02-71

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,817 , ´ñ±Û¼ö : 0

[¼­¿ï] ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä) : 2024-02-25

±³À°ÀÏÀÚ : 2024-02-25 ±³À°Àå¼Ò : ¼­¿ï´ëÇб³º´¿ø º»°ü ÁöÇÏ 1Ãþ ±èÁ¾±â Ȧ ±³À°ÁÖÁ¦ : ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä)ÁÖÃÖ±â°ü : ¼­

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,895 , ´ñ±Û¼ö : 0

[´ë±¸] 2023³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2023-04-20

±³À°ÀÏÀÚ : 2023-04-20 ±³À°Àå¼Ò : È£ÅÚ ÀÎÅÍºÒ°í ´ë±¸ ÄÁº¥¼ÇȦAB ¿Ü ±³À°ÁÖÁ¦ : 2023³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ ´ã

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,976 , ´ñ±Û¼ö : 0

[±¤ÁÖ] ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_2nd day : 2024-04-26

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ ÄÁº£¼Ç Ȧ ¿Ü 8°÷ ±³À°ÁÖÁ¦ : ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_2nd dayÁÖÃÖ±â°ü : ´ëÇѽŰæ¿Ü°ú

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,520 , ´ñ±Û¼ö : 0